More on ESALF
Data
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $25.00 |
|
|||
| Open | $25.00 | ||||
| 52 Wk High | $66.25 | ||||
| 52 Wk Low | $53.50 | ||||
| Day High | $25.00 | ||||
| Day Low | $25.00 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 299 | ||||
- Eisai invests £48M in UK manufacturing with government backing
- Eisai Announces Strategic Investment Supported by the UK Government's LSIMF
- Eisai Deepens Body of Clinical Evidence for LENVIMA(R) (Lenvatinib) Across Established Indications at ASCO 2026
- Merck and Eisai report failed kidney cancer drug trial results
- Merck & Co., Inc., Rahway, NJ, USA and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC
- Application Submitted for LENVIMA(R) (lenvatinib) in Japan Seeking Approval of Additional Dosage and Administration for Combination with WELIREG(R) (belzutifan) for Renal Cell Carcinoma that has Progr
- Eisai and Nuvation Bio get EU validation for lung cancer drug filing
- Eisai and Nuvation Bio Announce Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated by the European Medicines Agency
- Results from Real-World, Long-Term Treatment Persistence with LEQEMBI(R) (lecanemab-irmb) in the United States Presented at AD/PD(TM) 2026
- Eisai: Regarding Discontinuation of Administration of "Tazverik(R) Tablets 200mg" (tazemetostat hydrobromide)
Entities mentioned with ESALF
- FDA | View Related Stories »
- Twitter | View Related Stories »
- PDUFA | View Related Stories »
- Definitive Agreement | View Related Stories »
- Earnings | View Related Stories »
- S1 | View Related Stories »
- AdCom | View Related Stories »
- Morningstar, Inc. | View Related Stories »
- Show More...
